CVS
stock Healthcare Healthcare PlansOverall Concerning · 26%
- Fundamentals Weak
- Trajectory Steady
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Bullish 5 of 5 trend signals bullishRSI 56 — firm momentum, not yet overbought.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $91.39
- +2.11%
- Close
- $91.39
- +2.11%
- Current
- $91.39
- Prev close
- $89.50
- Today
- 5.54M
- 3-mo avg
- 7.83M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- May 676 days ago
- Next expected
- Jul 30in 9 days
Recent earnings dates
- May 6 76 days ago
- Feb 10 161 days ago
- Oct 29, 2025 265 days ago
- Jul 31, 2025 355 days ago
Past earnings dates come from CVS’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 53d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), CVS’s fundamentals read as weak overall.
At 40.1x, the price is steep relative to profit; the stock leans heavily on growth that has yet to arrive.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
A 2.9% yield is a healthy, generally sustainable level of cash income.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 0.4% margin is thin; little of each revenue dollar survives as profit.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 2.4% return on equity is weak; owners' capital is barely being put to work.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 0.7% return on assets is low; the asset base is generating little profit.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 2.37, the company leans heavily on borrowing, which adds risk if results weaken.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 0.84, short-term assets fall short of short-term bills; liquidity is tight.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 7.8% from the prior year: steady, modest expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income fell 61.7% from the prior year; profit is shrinking.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 53d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $292.1B | $322.5B | $357.8B | $372.8B | $402.1B |
| Net income | $8.0B | $4.3B | $8.3B | $4.6B | $1.8B |
| Diluted EPS | $6.02 | $3.26 | $6.47 | $3.66 | $1.39 |
| Dividend / share | $2.00 | $2.20 | $2.42 | $2.66 | $2.66 |
| Total assets | $233.0B | $228.3B | $249.7B | $253.2B | $253.5B |
| Total liabilities | $157.6B | $156.5B | $173.1B | $177.5B | $178.2B |
| Shareholder equity | $74.8B | $71.8B | $76.6B | $75.6B | $75.2B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $91.2B | $95.4B | $97.7B | $94.6B | $98.9B | $102.9B | $105.7B | $100.4B |
| Net income | $1.8B | $87.0M | $1.6B | $1.8B | $1.0B | -$4.0B | $2.9B | $2.9B |
| Diluted EPS | $1.41 | $0.07 | $1.30 | $1.41 | $0.80 | $-3.13 | $2.31 | $2.30 |
| Dividend / share | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 |
Leadershipsynced from SEC 59d ago
- Joyner J. David President, CEO and Chair · Director
- Newman Brian EVP, Chief Financial Officer
- Capozzi Heidi B EVP and Chief People Officer
- Clark James David SVP, Cont & Chief Acct Officer
- Compton-Phillips Amy EVP, Chief Medical Officer
- Khichi Samrat S. EVP, CPO and General Counsel
- Mandadi Tilak EVP, Chief Exp & Tech Officer
- Nelson Steven H EVP and President, Aetna
- Shah Prem S EVP and Group President
- Aguirre Fernando Director
- Balser Jeffrey R. Director
- Brown C David Ii Director
- Decoudreaux Alecia A Director
- Finucane Anne A. Director
- Gallina John E Director
- Kirby J Scott Director
- Mahoney Michael F Director
- Norwalk Leslie V Director
- Robbins Larry Director
- Sansone Guy P Director
- Shulman Douglas H. Director
Officers and board are drawn from CVS’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- May 18 Officer or director change reported in an 8-K
- May 6 +7.6% one-day move
- Apr 7 +6.7% one-day move
- Mar 19 New 6-month low (-14% off peak)
- Mar 19 Officer or director change reported in an 8-K
- Jan 27 −14.2% one-day move
- Dec 31, 2025 FY2025 net income −62% YoY
- Jul 24, 2025 −5.0% one-day move
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Dividendssynced from Yahoo 52d ago
- 2025 total
- $2.66
- 2026 so far
- $1.332 payments
- 2026 projected
- $2.66+0.0% vs 2025
Projection scales CVS’s declared payments so far this year up to the inferred cadence, then compares to last year’s total. Between payouts it is an estimate, not a guarantee.
Payment history
- Apr 23 $0.67
- Jan 22 $0.67
- Oct 23, 2025 $0.67
- Jul 22, 2025 $0.67
- Apr 22, 2025 $0.67
- Jan 23, 2025 $0.67
- Oct 21, 2024 $0.67
- Jul 22, 2024 $0.67
- Apr 19, 2024 $0.67
- Jan 19, 2024 $0.67
- Oct 19, 2023 $0.60
- Jul 20, 2023 $0.60
- Apr 20, 2023 $0.60
- Jan 19, 2023 $0.60
- Oct 20, 2022 $0.55
- Jul 21, 2022 $0.55
- Apr 21, 2022 $0.55
- Jan 20, 2022 $0.55
- Oct 21, 2021 $0.50
- Jul 22, 2021 $0.50
Recent SEC filingssynced from SEC 53d ago
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report